Hims & Hers Health (HIMS) EBITDA (2019 - 2026)

Hims & Hers Health has disclosed EBITDA across 8 years of filings, most recently posting -$98.8 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$98.8 million, down 299.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.5 million (down 110.63% YoY), and the FY2025 annual result was $131.0 million, up 4.09% from the prior year.
• EBITDA came in at -$98.8 million for Q1 2026 at Hims & Hers Health, down from $22.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $76.0 million in Q3 2024 to a low of -$98.8 million in Q1 2026.
• The 5-year median for EBITDA is $1.3 million (2023), against an average of $4.0 million.
• Across the five-year window, EBITDA jumped 1931.26% in 2024 and sank 299.04% in 2026, its largest moves.
• Hims & Hers Health's EBITDA stood at -$10.7 million in 2022, then jumped by 111.7% to $1.3 million in 2023, then surged by 1931.26% to $25.5 million in 2024, then decreased by 13.73% to $22.0 million in 2025, then tumbled by 549.69% to -$98.8 million in 2026.
• The last three EBITDA figures came in at -$98.8 million (Q1 2026), $22.0 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.